Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts
- 1 December 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (11) , 1522-1528
- https://doi.org/10.1097/00007890-200212150-00008
Abstract
Background. The recent results of clinical islet transplantation have improved substantially with the introduction of a more potent but less diabetogenic immunosuppressant protocol. The successful development of this protocol was based in part on the outcomes of studies reported herein, addressing the diabetogenic potential of a series of immunosuppressant agents used alone or in combination in a canine islet autograft model. Although it is recognized that failure to achieve long-term insulin independence in human islet allotransplantation has been multifactorial, with low engraftment mass, acute or chronic rejection, autoimmune recurrence, loss of islet-acinar integrity, heterotopic site, denervation, and insulin resistance all being implicated to varying degrees, avoidance of diabetogenic immunosuppression has been pivotal to the enhanced outcomes of clinical islet transplantation. We here explore the effects of clinically relevant doses of cyclosporine or tacrolimus when given alone or in combination with glucocorticoids on long-term canine islet autograft function. Method. Dogs (n=8) underwent total pancreatectomy, islet isolation, and intrasplenic autotransplantation and were normoglycemic with stable long-term graft function 3 months to 8 years posttransplant. The frequently sampled intravenous glucose tolerance test (FSIGT) was performed predrug (baseline), at 1 month of therapy (on drug), and again 1 month after withdrawal of therapy (postdrug). Results. Monotherapy treatments with low- or high-dose prednisone, Neoral, or tacrolimus had minimal impact on islet autograft function. The combination of Neoral and prednisone led to a marked impairment in glucose decay (25% decline from 1.77±0.2 to 1.24±0.2, P P P P <0.01). Conclusions. Immunosuppression must be specifically tailored for islet transplantation and be glucocorticoid free if insulin independence is to be sustained clinically.Keywords
This publication has 30 references indexed in Scilit:
- Human Islet Transplantation: UpdateWorld Journal of Surgery, 2001
- Metabolic Effects of Restoring Partial β-Cell Function After Islet Allotransplantation in Type 1 Diabetic PatientsDiabetes, 2001
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- Structural and functional changes resulting from islet isolation lead to islet cell deathSurgery, 1999
- Pancreatic islet cell survival following islet isolation: the role of cellular interactions in the pancreasJournal of Endocrinology, 1999
- Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant managementJournal of Molecular Medicine, 1999
- Reinnervation of Isolated Islets of Langerhans Transplanted beneath the Kidney Capsule in the RatCell Transplantation, 1994
- ACCELERATION OF CHRONIC FAILURE OF INTRAHEPATIC CANINE ISLET AUTOGRAFTS BY A SHORT COURSE OF PREDNISONE1Transplantation, 1994
- DIFFERENTIAL EFFECTS OF PREEXISTING UREMIA AND A SYNCHRONOUS KIDNEY GRAFT ON PANCREAS ALLOGRAFT FUNCTIONAL SURVIVAL IN RATSTransplantation, 1992
- BENEFICIAL AND DETRIMENTAL EFFECTS OF RBC-ADSORBED ANTILYMPHOCYTE GLOBULIN AND PREDNISONE ON PURIFIED CANINE ISLET AUTOGRAFT AND ALLOGRAFT FUNCTIONITransplantation, 1991